Ligufalimab is a monoclonal antibody commercialized by Akeso, with a leading Phase II program in Esophageal Squamous Cell Carcinoma (ESCC). According to Globaldata, it is involved in 11 clinical trials, of which 1 was completed, 8 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Ligufalimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Ligufalimab is expected to reach an annual total of $34 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ligufalimab Overview
Akeso Overview
Akeso is a clinical-stage biopharmaceutical company that focuses on in-house discovery and development of mono and bi-specific antibody drugs. The company’s product pipeline includes Ak101 and Ak111 targeting plaque psoriasis; Ak102 for the treatment of hypercholesterolemia; Ak104 against cancer; Ak105 for treating anlotinib; and Ak112 against solid tumors. It also offers kangfang integrated development platform (ACE Platform) which covers all drug R & D, including target verification, antibody discovery and also development functions. The company works in partnership with MERCK & CO Inc, Dawnrays Pharmaceutical Holdings Ltd, Sino Biopharmaceutical Ltd and China Biopharma. Akeso is headquartered in Zhongshan, Guangdong, China
The company reported revenues of (Renminbi) CNY837.7 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of CNY225.6 million in FY2021. The operating loss of the company was CNY1,378.9 million in FY2022, compared to an operating loss of CNY1,247.8 million in FY2021. The net loss of the company was CNY1,168.4 million in FY2022, compared to a net loss of CNY1,074.9 million in FY2021.
For a complete picture of Ligufalimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
